Fiche publication
Date publication
novembre 2025
Journal
European urology oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr EYMARD Jean-Christophe
,
Dr MOUILLET Guillaume
Tous les auteurs :
Oudard S, Timsit MO, Maillet D, Mouillet G, Campedel L, Colomba E, Dourthe LM, Eymard JC, Gobert A, Jamet C, Joly C, Serrate C, Ploussard G
Lien Pubmed
Résumé
Over the past 15 yr, significant progress has been made in the management of prostate cancer (PC), including the development of chemotherapy, androgen receptor pathway inhibitors (ARPIs), and, more recently, radium-223 radioligand therapy. However, metastatic PC is still the third leading cancer-related cause of death among men in Europe, with a 5-yr survival rate of ∼30% and median overall survival (OS) of <3 yr for castration-resistant PC (CRPC). Current strategies are moving towards personalised treatment, with the emergence of PARP inhibitors (PARPi) that exploit a vulnerability in the DNA repair system in patients with alterations in genes involved in homologous recombination.
Mots clés
Androgen receptor pathway inhibitor, BRCA gene, DNA repair, PARP inhibitors, Prostate cancer
Référence
Eur Urol Oncol. 2025 11 10;:
